Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study.

• Tác giả: Mitsuhiro Fujishiro, Hiroyuki Isayama, Yukiko Ito, Yasushi Kojima, Saburo Matsubara, Dai Mohri, Yousuke Nakai, Hiroki Oyama, Kei Saito, Takashi Sasaki, Tatsuya Sato, Kaoru Takagi, Tsuyoshi Takeda, Shun Tezuka, Nobuo Toda, Ko Tomishima, Makoto Ueno, Natsuyo Yamamoto
• Ngôn ngữ: eng
• Ký hiệu phân loại: 297.1248 Sources of Islam
• Thông tin xuất bản: United States : Pancreas , 2025
• Bộ sưu tập: NCBI
• ID: 15504

Tóm tắt

 PURPOSE: The aim of this multicenter retrospective study was to evaluate the impact of statin use on clinical outcomes in patients with unresectable pancreatic cancer (PC) receiving gemcitabine plus nab-paclitaxel (GnP) in a large Japanese cohort. MATERIALS AND METHODS: We retrospectively reviewed the medical records including data on the use of concomitant medications in patients with unresectable PC receiving GnP between January 2015 and January 2019 at 10 hospitals. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were evaluated. RESULTS: A total of 1682 patients were included in the analysis
  of which 322 patients (19%) received statins and 1360 (81%) did not receive statin. The median PFS and OS were 7.5 versus 7.3 months (P = 0.87) and 15.1 versus 14.4 months (P = 0.48) in cases with and without statin use. The use of statin was not associated with PFS (hazard ratio, 1.01
  95% confidence interval, 0.85-1.18, P = 0.93) or OS (hazard ratio, 1.05
  95% confidence interval, 0.91-1.21, P = 0.47) in the multivariable analyses. PFS and OS did not significantly differ by liposolubility of statins, either. CONCLUSIONS: Stain use was not associated with PFS or OS in patients with unresectable PC receiving GnP.